Concepedia

The effects of cotrimoxazole or tenofovir co‐administration on the pharmacokinetics of maraviroc in healthy volunteers

Deborah Russell, Lyndsey A. Whitlock, Caroline E. Ridgway, Gary J. Muirhead

British Journal of Clinical Pharmacology · 2008 · 21 citations · 25 references

DOIFull text

Open access

Abstract

Neither cotrimoxazole nor tenofovir caused a clinically significant effect on the pharmacokinetics of maraviroc. Maraviroc 300 mg b.i.d. was well tolerated when co-administered with either cotrimoxazole or tenofovir.

References

25

Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection

Rong Liu, William A. Paxton, Sunny Choe et al. · Cell · 1996 · 3.1K citations · Full text

, , +9

CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1

Ghalib Alkhatib, Christophe Combadière, Christopher C. Broder et al. · Science · 1996 · 2.7K citations

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations · Full text

, , +19

Basic and clinical pharmacology

Jim Traynor · Journal of Pharmaceutical and Biomedical Analysis · 1988 · 1.1K citations

, , +6

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1

Gerd Fätkenheuer, Anton Pozniak, Margaret Johnson et al. · Nature Medicine · 2005 · 490 citations

, , +10